NCT03358472 2025-12-03Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)Incyte CorporationPhase 3 Completed89 enrolled 14 charts
NCT02959437 2025-10-21Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)Incyte CorporationPhase 1/2 Terminated70 enrolled 14 charts
NCT02752074 2025-08-24A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)Incyte CorporationPhase 3 Completed706 enrolled 17 charts
NCT03322540 2025-08-22Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)Incyte CorporationPhase 2 Completed154 enrolled 14 charts
NCT03361865 2025-08-22Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)Incyte CorporationPhase 3 Completed93 enrolled 13 charts
NCT03374488 2025-08-22Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial CarcinomaIncyte CorporationPhase 3 Completed84 enrolled 13 charts
NCT02327078 2025-08-14A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)Incyte CorporationPhase 1/2 Completed307 enrolled 27 charts
NCT03260894 2025-07-29Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)Incyte CorporationPhase 3 Completed129 enrolled 13 charts